Chemomab Therapeutics receives FDA Fast Track Designation for CM-101

Chemomab Therapeutics announced that the U.S. FDA has granted CM-101 Fast Track designation for the treatment in adult patients of primary sclerosing cholangitis, a fibrotic liver disease that can result in liver transplant, cancer and early death.